ARTICLE | Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
January 4, 2023 12:29 AM UTC
Cancer drug discovery company ZielBio Inc. hired Alan Bash as CEO and a director. Bash, a 22-year veteran of Bristol Myers Squibb Co. (NYSE:BMY), was most recently president and CEO of Checkmate Pharmaceuticals Inc., which was acquired by Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).
Rafael Amado left CAR T cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) to become president, head of global oncology R&D of Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688). Allogene hired Zachary Roberts to succeed Amado as EVP of R&D; he was CMO of Instil Bio Inc. (NASDAQ:TIL), before which he held roles of increasing responsibilities at Kite Pharma, a Gilead Sciences Inc. (NASDAQ:GILD) company...